Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas
- PMID: 2899530
- DOI: 10.1016/s0016-5085(88)80025-8
Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas
Abstract
Somatostatin receptor frequency was evaluated in 12 human exocrine pancreatic carcinomas taken after surgery. The tumors were analyzed by receptor autoradiography on tissue sections and by in vitro binding techniques on tumor homogenates. None of the tested human pancreatic carcinomas was shown to possess specific somatostatin receptors. In comparison, five single tumors taken from rats transplanted with the rat pancreatic adenocarcinoma CA 20948 were found to contain specific high-affinity somatostatin receptors. Also, human endocrine pancreatic tumors, i.e., two insulinomas, did contain somatostatin receptors under identical experimental conditions. These data confirm previous results with other tumors, documenting the absence of somatostatin receptors in highly malignant human carcinomas. They also may represent an explantation at the molecular level for the lack of therapeutic effect of somatostatin analogues such as SMS 201-995 seen in patients with advanced exocrine pancreatic carcinomas.
Similar articles
-
Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors.J Clin Endocrinol Metab. 1987 Dec;65(6):1127-34. doi: 10.1210/jcem-65-6-1127. J Clin Endocrinol Metab. 1987. PMID: 2824549
-
Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.Cancer Res. 1990 Sep 15;50(18):5969-77. Cancer Res. 1990. PMID: 2168286
-
Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.J Clin Endocrinol Metab. 1990 Sep;71(3):566-74. doi: 10.1210/jcem-71-3-566. J Clin Endocrinol Metab. 1990. PMID: 2168430
-
In vitro and in vivo detection of somatostatin receptors in human malignant tissues.Acta Oncol. 1991;30(4):463-8. doi: 10.3109/02841869109092402. Acta Oncol. 1991. PMID: 1649613 Review.
-
In vitro detection of somatostatin receptors in human tumors.Metabolism. 1992 Sep;41(9 Suppl 2):104-10. doi: 10.1016/0026-0495(92)90042-9. Metabolism. 1992. PMID: 1355582 Review.
Cited by
-
Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro.World J Gastroenterol. 2004 Feb 1;10(3):393-9. doi: 10.3748/wjg.v10.i3.393. World J Gastroenterol. 2004. PMID: 14760765 Free PMC article.
-
Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.Br J Cancer. 1999 Feb;79(3-4):535-7. doi: 10.1038/sj.bjc.6690084. Br J Cancer. 1999. PMID: 10027326 Free PMC article. Clinical Trial.
-
Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.J Cancer Res Clin Oncol. 1997;123(1):45-52. doi: 10.1007/BF01212614. J Cancer Res Clin Oncol. 1997. PMID: 8996540 Free PMC article. Review.
-
Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5.Mol Endocrinol. 2012 Jul;26(7):1225-34. doi: 10.1210/me.2012-1095. Epub 2012 Jun 5. Mol Endocrinol. 2012. PMID: 22669743 Free PMC article.
-
Immunohistochemical localization of somatostatin receptors sst2A in human tumors.Am J Pathol. 1998 Jul;153(1):233-45. doi: 10.1016/S0002-9440(10)65564-2. Am J Pathol. 1998. PMID: 9665484 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical